Welcome to our dedicated page for Pharvaris news (Ticker: PHVS), a resource for investors and traders seeking the latest updates and insights on Pharvaris stock.
Pharvaris N.V. reports developments as a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists for bradykinin-mediated diseases, including hereditary angioedema and acquired angioedema due to C1 inhibitor deficiency. Its lead program, deucrictibant, is being developed in immediate-release capsule and extended-release tablet forms for on-demand and prophylactic treatment settings.
Recurring updates include clinical data from the RAPIDe and CHAPTER study programs, patient-reported outcome research, scientific publications, presentations at allergy and immunology meetings, financial results, strategic priorities, shareholder voting matters and capital-structure disclosures.
Summary not available.
Summary not available.
Pharvaris (Nasdaq: PHVS) reported its financial results for Q4 and full year 2022, revealing a loss of €39.2 million for Q4 and a total loss of €76.3 million for the year. Cash and equivalents stood at €162 million as of December 31, 2022. Upcoming milestones include the release of top-line data from the CHAPTER-1 Phase 2 study of PHVS416 for hereditary angioedema (HAE), expected in 2H2023, and the completion of a non-clinical toxicology study by YE2023. The company has also adopted deucrictibant as the nonproprietary name for PHA121.
Pharvaris (Nasdaq: PHVS) announced positive results from its Phase 2 RAPIDe-1 trial of PHVS416 for treating hereditary angioedema (HAE) at the 2023 HAEi Regional Conference APAC. The trial, which included 74 participants and evaluated 147 HAE attacks, demonstrated significant symptom reduction at four hours post-treatment with PHVS416 compared to placebo, achieving a nominal p-value 0.0001. All primary and key secondary endpoints were met, with participants using less rescue medication. PHVS416 was well tolerated, with minimal treatment-related adverse events. These findings support ongoing development as a potential oral on-demand therapy for HAE attacks.
ZUG, Switzerland, March 02, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS) announced participation in two investor conferences in March. The first event is the BioCapital Europe 2023, taking place in Amsterdam on March 9, 2023, at 11:00 a.m. CET. The second is the Oppenheimer 33rd Annual Healthcare Conference, a virtual presentation scheduled for March 13, 2023, at 2:00 p.m. CET. A live audio webcast of the latter will be accessible on Pharvaris' website, with a replay available for 30 days. Pharvaris specializes in developing oral bradykinin-B2-receptor antagonists for treating hereditary angioedema (HAE), aiming to provide effective treatment options.
Pharvaris (Nasdaq: PHVS) announced positive data from its Phase 2 RAPIDe-1 study of PHVS416, an oral bradykinin-B2-receptor antagonist for hereditary angioedema (HAE), presented at the AAAAI Annual Meeting in February 2023. The trial enrolled 74 participants, showing that PHVS416 significantly improved symptoms during HAE attacks, reducing the mean 3-symptom composite score (p0.0001). Participants required less rescue medication when on PHVS416 versus placebo. The results support further development of PHVS416 as an on-demand therapy for HAE.Pharvaris aims to offer effective, convenient treatment options for HAE patients worldwide.
Pharvaris (Nasdaq: PHVS), a clinical-stage company, is focused on developing oral bradykinin-B2-receptor antagonists for treating and preventing hereditary angioedema (HAE) attacks. The company announced its participation in the SVB Securities Global Biopharma Conference, scheduled virtually from February 14–16, 2023. Pharvaris will present on February 15, at 2:40 p.m. CEST (8:40 a.m. EST), with a live audio webcast accessible on their Investor page. A replay will be available for 30 days post-presentation. Pharvaris aims to provide safe and effective treatment options for all HAE sub-types, leveraging its specialized knowledge in rare diseases.
Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on oral bradykinin-B2-receptor antagonists for hereditary angioedema (HAE), provided key business updates. The FDA received meeting minutes and will require a 26-week rodent toxicology study to resolve clinical holds. Positive top-line data from RAPIDe-1 was released in December 2022, with the FDA allowing final U.S. participant dosing. Top-line data from the CHAPTER-1 Phase 2 study is expected in 2H2023. The company maintains a cash runway into 4Q2024.
Pharvaris (PHVS) announced positive top-line data from the Phase 2 RAPIDe-1 study, showing significant efficacy of PHVS416 as an oral treatment for hereditary angioedema (HAE) attacks. The company is actively resolving clinical holds on PHA121 in the U.S. following a Type A meeting with the FDA. Pharvaris holds €198 million in cash as of September 30, 2022, although R&D expenses increased to €14.1 million. Future top-line data from CHAPTER-1, another Phase 2 study, is expected in the second half of 2023, aiming to evaluate PHVS416 prophylactically.
Pharvaris (Nasdaq: PHVS) announced positive results from the RAPIDe-1 Phase 2 clinical study of PHVS416, a novel oral treatment for hereditary angioedema (HAE). Key findings include:
- The primary endpoint was met, showing significant symptom relief.
- All secondary endpoints were achieved, demonstrating rapid onset and efficacy.
- PHVS416 was well tolerated across all dose levels.
Overall, the study indicates PHVS416's potential as an effective on-demand therapy for HAE attacks.